Table 5. Baseline and efficacy and safety data of the Regimen Complexity Analysis.
| Regimen | 2 Drugs (A) N = 45 | 3 Drugs (B) N = 111 | 4 Drugs (C) N = 124 | >4 Drugs (D) N = 40 |
| RAMs NA, mean | 6.2 | 5.4 | 5.2 | 7.6 |
| RAMs NNRTI, mean | 1.5 | 1.5 | 1.4 | 2.7 |
| RAMs PI, mean | 5.8 | 8.2 | 7.5 | 12.2 |
| GSS, mean | 1.6 | 1.9 | 2.1 | 2.1 |
| % HIV RNA <50 copies/mL | 88.9 | 87.8 | 87.9 | 80 |
| * Δ CD4+ T cells/mm3, mean (95% CI), P | +270.2, (134.5–406.0)P<0.0001 | +214.2 (164.5–267.9)P<0.0001 | +216.5 (141.5–281.4)P<0.0001 | +244.1 (170.6–317.7)P<0.0001 |
| * Δ Total Cholesterol, mg/dL, mean (95% CI), P | +17.0 (−3.4 – +38.5)P = 0.10 | +26.0 (12.3–39.7)P = 0.0002 | +18.7 (5.7–31.7)P = 0.0049 | +34.4 (16.3–66.1)P = 0.0016 |
| * Δ Triglycerides, mg/dL, mean (95% CI), P | −41.9 (−94 – +10.2)P = 0.11 | +5.7 (−43.1 – +53)P = 0.82 | −14.8 (−48.9 – +19.3)P = 0.39 | −3.8 (−69.6 – +45.1)P = 0.69 |
| * Δ ALT, IU/L, mean (95% CI), P | −1.4 (−24.8 – +11.4)P = 0.46 | −2.2 (−14.1 – +9.8)P = 0,72 | −1.4 (−12,7 – +9,8)P = 0,80 | +1.1 (−24,2 – +26,3)P = 0,93 |
RAM = resistance-associated mutations; NA = nucleoside (nucleotide) analogues; NNRTI = non nucleoside reverse transcriptase inhibitor; PI = protease inhibitor; GSS 0 genotypic sensitivity score; ALT = alanine aminotranferase, 95% CI = Confidence Interval.
*
Δ values are mean differences between baseline and w 96.